

EKF Diagnostics Holdings plc
("EKF" or the "Company")

**AGM Statement
& Positive Q1 Trading update**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an update to shareholders ahead of its Annual General Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD at 11.00 am.

The Company is providing a facility for shareholders to listen in to the AGM, either online or telephonically (in a non-voting capacity), and there will be an opportunity for shareholders to ask questions. For dial-in details and to submit any questions please contact Walbrook PR via email at ekf@walbrookpr.com or call +44 (0)20 7933 8780.

Executive Chair's AGM statement

I am delighted to announce that trading in the early part of the year ended 31 December 2025 ("FY 2025") is in-line with management expectations.

Last year we concluded our rationalisation process and in the new financial year we are experiencing the benefits of a more simplified business with greater commercial focus on higher margin products and services. As a result adjusted EBITDA¹ performance has held up well, against the head winds of tariffs and unfavourable exchange rates in the US.

The implementation of our five-year strategic development has begun in earnest and as we recently announced, the key area of growth within our point-of-care division is Hematology. We continue to exploit our no. 2 position in Hemoglobin point-of-care testing and we currently have a strong order book, particularly for analysers across Latin America.

Within our Life Sciences division sales of β -HB remain robust and our pipeline for contract manufacturing and fermentation opportunities has significantly improved with a number of high value prospects currently in discussions.

Cash generation continues to be very strong even with the planned investment for growth that we have incorporated into our five-year plan, as well as the use of surplus cash to undertake a successful £1m share buyback programme. Cash as of 9 May is at £15.7m and we continue to expect cash to finish the year significantly higher than FY 2024 levels.

We are very excited about the prospects of the business and we remain on track to deliver growth at the revenue and adjusted EBITDA levels for FY 2025 in-line with market expectations.

¹adjusted earnings before interest, tax, depreciation and amortisation, share-based payments and exceptional items

EKF Diagnostics Holdings plc
Julian Baines, Executive Chair / Stephen Young, CFO

www.ekfdiagnostics.com
via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)
Phil Davies / Oliver Platts

Tel: +44 (0)20 7496 3000

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654





About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMSFLESUEISEEI